Common-Size Income Statement
Quarterly Data
Cytokinetics Inc., common-size consolidated income statement (quarterly data)
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
The financial trajectory of the entity is characterized by extreme volatility in revenue composition and a significant escalation in operating expenses relative to total revenue. While revenues have historically been dominated by research and development (R&D) and licensing agreements, the scale of expenditures has grown exponentially, leading to a substantial widening of net losses as a percentage of revenue over the analyzed period.
- Revenue Composition and Stability
- Revenue streams demonstrate a high degree of instability and a lack of consistent product-based income. From early 2018 through early 2020, R&D revenues were the primary driver, often accounting for 100% of total revenue. In later periods, the revenue mix shifted toward sporadic license revenues and milestone payments, such as the license revenue spikes observed in September 2020 (87.56%) and December 2021 (98.66%). The emergence of realization of revenue participation rights in June 2022 further highlights a reliance on non-recurring financial events rather than scalable operational growth.
- Operating Expense Trends
- There is a pronounced upward trend in operating expenses when measured as a percentage of revenue. R&D and General and Administrative (G&A) costs have consistently exceeded total revenue, indicating a heavy investment phase. This trend accelerated dramatically in 2023; R&D expenses surged from -1,721.68% in March 2023 to -21,833.86% by September 2023. Similarly, G&A expenses climbed to -10,611.38% in the final quarter of the data set. This suggests a period of intense spending that is not being offset by proportional revenue growth.
- Operating and Net Profitability
- Operating income has remained almost exclusively negative, with a singular exception in September 2020 where a modest positive margin of 12.44% was achieved. The operating loss ratio deteriorated from -496.03% in March 2018 to -32,345.24% in September 2023. The net loss closely mirrors this operational decline, reaching -34,238.62% of revenue in the most recent quarter, reflecting a critical disconnect between the current revenue base and the cost of operations.
- Non-Operating Items and Interest Dynamics
- Interest and other income, net, have shown a significant increase in the most recent periods, reaching 1,809.26% of revenue in September 2023. This indicates that a substantial portion of the entity's current financial support is derived from interest-bearing assets rather than core operations. Conversely, interest expenses and non-cash interest on liabilities related to revenue participation rights have remained persistent burdens, though they are overshadowed by the massive increase in operating losses. Occasional debt settlement losses in 2022 also contributed to the overall negative financial position.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?